Jardiance

EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
Fierce Pharma
EASD
Boehringer Ingelheim
Eli Lilly
Jardiance
diabetes
Flag link:
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
Fierce Pharma
JNJ
Invokana
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
Flag link:
BI, Lilly hit the streets to talk up Jardiance's cardiovascular benefits
BI, Lilly hit the streets to talk up Jardiance's cardiovascular benefits
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Jardiance
drug ads
DTC advertising
Flag link:
For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive
For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive
Medical Marketing and Media
diabetes
blood sugar
competition
Novo Nordisk
Victoza
Eli Lilly
Jardiance
Invokana
JNJ
Flag link:
AstraZeneca, Boehringer cry 'no class effect' after Johnson & Johnson's Invokana doubles amputations in study
AstraZeneca, Boehringer cry 'no class effect' after Johnson & Johnson's Invokana doubles amputations in study
Fierce Pharma
AstraZeneca
Boehringer Ingelheim
JNJ
Invokana
diabetes
Jardiance
amputation
Flag link:
J&J's Invokana lowers CV risk, but by enough to compete?
J&J's Invokana lowers CV risk, but by enough to compete?
BioPharma Dive
JNJ
Invokana
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Flag link:
ADA: Merck, Pfizer notch success, but late with SGLT-2 data
ADA: Merck, Pfizer notch success, but late with SGLT-2 data
BioPharma Dive
diabetes
Merck
Pfizer
SGLT2 inhibitor
Januvia
Invokana
Farxiga
Jardiance
Eli Lilly
Boehringer Ingelheim
AstraZeneca
JNJ
Flag link:
J&J Drug Prevents Heart Attacks At Cost Of Amputated Toes
J&J Drug Prevents Heart Attacks At Cost Of Amputated Toes
Forbes
JNJ
heart attacks
Invokana
diabetes
amputation. Eli Lilly
Boehringer Ingelheim
Jardiance
Flag link:
ADA preview: 5 things to watch in diabetes
ADA preview: 5 things to watch in diabetes
BioPharma Dive
ADA
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Lantus
Tresiba
JNJ
Novo Nordisk
PCSK9 inhibitors
Amgen Regeneron
Sanofi
Apple
Google
insulin
Flag link:
2 Reasons Eli Lilly is Getting Crushed
2 Reasons Eli Lilly is Getting Crushed
Barron's
Eli Lilly
earnings
Jardiance
diabetes
baricitinib
Flag link:
Diabetes meds from AZ, J&J and Lilly sharply cut death rates in real-world analysis
Diabetes meds from AZ, J&J and Lilly sharply cut death rates in real-world analysis
Fierce Pharma
AstraZeneca
JNJ
Eli Lilly
Boehringer Ingelheim
diabetes
Farixga
Invokana
Jardiance
SGLT2 inhibitor
Flag link:
Merck and Pfizer prep for battle with SGLT2, combo diabetes filings
Merck and Pfizer prep for battle with SGLT2, combo diabetes filings
Fierce Pharma
Merck
Pfizer
SGLT2 inhibitor
diabetes
ertugliflozin
Jardiance
Boehringer Ingelheim
Eli Lilly
JNJ
Invokana
AstraZeneca
Farxiga
Flag link:
ADA guidelines highlight new Jardiance label
ADA guidelines highlight new Jardiance label
BioPharma Dive
ADA
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Novo Nordisk
Victoza
Flag link:
BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists
BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists
Medical Marketing and Media
Boehringer Ingelheim
Eli Lilly
cardiologists
diabetes
Jardiance
Flag link:
Lilly Shares Spike On Jardiance Approval (LLY)
Lilly Shares Spike On Jardiance Approval (LLY)
Investopedia
Eli Lilly
FDA
Jardiance
type 2 diabetes
cardiovascular death
Flag link:
Fate of Lilly's Jardiance franchise rests on FDA's delayed heart-benefits indication
Fate of Lilly's Jardiance franchise rests on FDA's delayed heart-benefits indication
Fierce Pharma
Eli Lilly
Jardiance
FDA
diabetes
Boehringer Ingelheim
Flag link:
Eli Lilly Has Catalysts Ahead
Eli Lilly Has Catalysts Ahead
TheStreet.com
Eli Lilly
earnings
solamezumab
Jardiance
Flag link:
U.S. panel backs claim Lilly diabetes drug cuts cardiac death
U.S. panel backs claim Lilly diabetes drug cuts cardiac death
Yahoo/Reuters
FDA
advisory panels
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
Flag link:
Is Merck & Co., Inc Januvia In Trouble? FDA Panel Decides Tomorrow
Is Merck & Co., Inc Januvia In Trouble? FDA Panel Decides Tomorrow
Bidness, ETC
Merck
Januvia
diabetes
FDA
advisory panels
Jardiance
Eli Lilly
Flag link:
FDA panel to vote whether diabetes drug cuts cardiac death
FDA panel to vote whether diabetes drug cuts cardiac death
Yahoo/Reuters
FDA
advisory panels
diabetes
Eli Lilly
Boehringer Ingelheim
Jardiance
Flag link: